Alzheimer’s disease

BioArctic’s Q2 2025 royalties surged to SEK 162.5 million due to strong Leqembi (lecanemab) sales, developed with Eisai, reaching JPY 23.1 billion. This included a one-time China stockpiling effect of JPY 5.3 billion. Excluding this, sales were JPY 17.8 billion, with royalties of approximately SEK 125 million. BioArctic will release its full Q2 report on August 28, focusing on Leqembi’s sustainable growth. Leqembi, targeting early Alzheimer’s, is approved in 46 countries and under review in 10 more.